Myecfo LLC Takes $529,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Myecfo LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 18,497 shares of the biotechnology company’s stock, valued at approximately $529,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Washington Trust Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $25,000. Neo Ivy Capital Management bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $41,000. Quest Partners LLC purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at about $45,000. Friedenthal Financial bought a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $51,000. Finally, Van ECK Associates Corp lifted its stake in Arrowhead Pharmaceuticals by 22.9% during the fourth quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 447 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Victoria Vakiener sold 1,799 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now directly owns 30,205 shares in the company, valued at $704,078.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They set a “neutral” rating and a $31.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 11th. Morgan Stanley reduced their price target on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a research report on Monday, May 13th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, June 26th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.89.

Arrowhead Pharmaceuticals Trading Down 3.2 %

ARWR traded down $0.83 on Tuesday, reaching $25.22. The stock had a trading volume of 805,985 shares, compared to its average volume of 1,333,021. The company has a market cap of $3.13 billion, a P/E ratio of -5.93 and a beta of 0.94. The business’s 50-day moving average price is $24.49 and its two-hundred day moving average price is $28.33. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.67 and a 12-month high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same quarter in the previous year, the business posted $0.45 EPS. Arrowhead Pharmaceuticals’s quarterly revenue was down 100.0% compared to the same quarter last year. As a group, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.05 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.